Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma

We evaluated the relationship between benralizumab (30 mg every 4 and 8 weeks (Q4W, Q8W)) pharmacokinetic (PK) exposure and end points of asthma exacerbation rates (AERs) and change from baseline in prebronchodilator forced expiratory volume in 1 second (FEV (1)) for patients with severe, uncontroll...

Descripción completa

Detalles Bibliográficos
Autores principales: Chia, Yen Lin, Yan, Li, Yu, Binbing, Wang, Bing, Barker, Peter, Goldman, Mitchell, Roskos, Lorin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767326/
https://www.ncbi.nlm.nih.gov/pubmed/30661249
http://dx.doi.org/10.1002/cpt.1371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767326/
https://www.ncbi.nlm.nih.gov/pubmed/30661249
http://dx.doi.org/10.1002/cpt.1371

Ejemplares similares